Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
St. Michael's Hospital · University of Toronto · +7 more institutions
Abstract
A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 other countries. As of February 27, 2020, over 82,000 cases of COVID-19 were reported, with > 2800 deaths. No specific therapeutics are available, and current management includes travel restrictions, patient isolation, and supportive medical care. There are a number of pharmaceuticals already being tested [1, 2], but a better understanding of the underlying pathobiology is required. In this context, this article will briefly review the rationale for…
Citation impact
- FWCI
- 66.59
- Percentile
- 100%
- References
- 34
Authors
5- HZHaibo ZhangCorresponding
St. Michael's Hospital, University of Toronto, First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University
- JPJosef Penninger
Institute of Molecular Biotechnology, Austrian Academy of Sciences, University of British Columbia
- YLYimin Li
First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University
- NZNanshan Zhong
First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University
- ASArthur S. Slutsky
St. Michael's Hospital, First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Artificial Intelligence in Medicine (Canada), Guangzhou Medical University
Topics & keywords
- Medicine
- Angiotensin-converting enzyme 2
- Peptidyl-Dipeptidase A
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Pain medicine
- Coronavirus disease 2019 (COVID-19)
- 2019-20 coronavirus outbreak
- Anesthesiology
Funding
- NSNational Science FoundationAwards: 2018GZR0201002, 81270125, 81490530
- NNNational Natural Science Foundation of ChinaAwards: 81270125, 2018GZR0201002, 81490530
- GRGuangzhou Regenerative Medicine and Health Guangdong LaboratoryAward: 2018GZR0201002
- CICanadian Institutes of Health ResearchAward: FDN143285
- IOInstitute of Circulatory and Respiratory HealthAward: FDN143285